MT2024-41: A Phase I Study of FT536 in Combination with Isatuximab in Patients with Relapsed or Refractory Myeloid Neoplasms and Multiple Myeloma.

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.